EGFR and cancer: Importantly, MR30 showed significantly stronger potency than the clinical EGFR inhibitor gefitinib or the equimolar combination of EGFR and MGMT inhibitors (gefitinib + O6-BG) on 5 out of 7 EGFR expressing cancer cell lines (p<0.01).